.Nature Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin resulted in improved progression-free as well as general survival, triggering FDA approval and a brand-new procedure option for clients.